Guggenheim Initiates Coverage On Retension Pharmaceuticals with Buy Rating, Announces Price Target of $55
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsInitiationPrice Target
Guggenheim analyst Seamus Fernandez initiates coverage on Retension Pharmaceuticals (NASDAQ:RTSN) with a Buy rating and announces Price Target of $55.
Guggenheim analyst Seamus Fernandez initiates coverage on Retension Pharmaceuticals (NASDAQ:RTSN) with a Buy rating and announces Price Target of $55.